Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1143-1168

  Sedlacek, Hans Harald ^a   Czech, Jörg ^a   Naik, Ramachandra ^b   Kaur, Gurmeet ^c   Worland, Peter ^c   Losiewicz, Michael ^c   Parker, Bernard ^c   Carlson, Bradley ^c   Smith, Adaline ^c   Senderowicz, Adrian ^c   Sausville, Edward ^c  

^a Behringwerke AG   (Germany)

^b Hoechst Marion Roussel Limited   (India)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cyclin dependent kinase; Flavopiridol; inhibitor; pharmacokinetic; preclinical activity; toxicity; tumor therapy

Indexed keywords

CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; FLAVONE DERIVATIVE; FLAVOPIRIDOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0029807115     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.6.1143     Document Type: Article

References (133)

1. Kattige SL, Naik RG, Lakdawalla AD, Dohadwalla AN, Rupp RH and Souza NJ: Synthesis of 4H-1-Benzopyran-4-on derivatives and pharmaceutical use. DE 361 2337, 1986.
2. Naik RG, Kattige Sl, Bhat SV, Alrejy B, de Souza NJ and Rupp RH: An antiinflammatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 44: 2081-2086, 1988.
3. Naik RG, Lal B, Rupp RH, Sedlacek HH, Dickneite G and Czech J: New 4H-1-Benzopyran-4-on derivatives and pharmaceutical use. DE 383 6676; EP 036 6061; USP 528 4856, 1988.
4. Graziani Y, Erikson E and Erikson RL: The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 135: 583-589, 1983.
5. Boutin JA: Tyrosine protein kinase inhibition and cancer. Int J Biochem 26: 1203-1226, 1994.
6. Müller R: Transcriptional regulation during the mammalian cell cycle. Trends Genet 11: 173-178, 1995.
7. Sporn MB and Roberts AB: Autocrine growth factors and cancer. Nature 313: 745-747, 1985.
8. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, William RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
9. Marco Di E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson ST and Fiore Di PP: Autocrine interaction between TGFα and the EGF receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831-838, 1989.
10. Lee PL, Johnson DE, Cousens LS, Fried VA and Williams LT: Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 245: 57-60, 1989.
11. Yarden Y and Ullrich A: Molecular analysis of signal transduction by growth factors. Biochemistry 27: 3113-3119, 1988.
12. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Progress in Cell Cycle Res 1: 351-363, 1995.
13. Sedlacek HH, Hoffmann D, Czech J, Kolar C, Seemann G, Güssow D and Bosslet K: The change in research for the therapy of tumors. Chimia 45: 311 -316, 1991.
14. Czech J, Hoffmann D, Naik R and Sedlacek HH: Antitumoral activity of flavone L86 8275. Int J Oncol 6: 31-36, 1995.
15. cdc2 kinase by the flavone L86 8275 in breast carcinoma cells. Biochem Pharmacol 46: 1831-1840, 1993.
16. Losiewicz MD, Carlson BA, Kaur G, Sausville EA and Worland PJ: Potent inhibition of cdc2 kinase activity by the flavonoid L86 8275. Biochem Biophys Res Commun 201: 589-595, 1994.
17. Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (cdk) 2 and ckd4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
18. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek HH, Myers C, Czech J, Naik R and Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86 8275. J Natl Cancer Inst 84: 1736-1740, 1992.
19. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M and Hidaka H: Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 37: 2987-2992, 1988.
20. Casnellie JE: Protein kinase inhibitors: probes for the functions of protein phosphorylation. Adv Pharmacol 22: 167-205, 1991.
21. End DW, Look RA, Schaffer NL, Balles EA and Perisco JA: Non-selective inhibition of mammalian protein kinases by flavonoids in vitro. Res Comm Chem Pathol Pharmacol 56: 75-86, 1987.
22. Barret JM, Ernould AP, Rouillon MH, Ferry G, Genton A and Boutin JA: Studies of the potency of protein kinase inhibitor on ATPase activities. Chem Biol Interact 86: 17-27, 1993.
23. Okura A, Arakawa H, Oka H, Yoshainari T and Monden Y: Effect of genistein on topoisomerase activity and the growth of Val 12 H-ras-transformed NIH3T3 cells. Biochem Biophys Res Commun 157: 183-189, 1988.
24. Linassier C, Pierre M, Le Pecq JB and Pierre J: Mechanisms of action in HIH-3T3 cells of genistein, an inhibitor of EGF-receptor tyrosine kinase activity. Biochem Pharmacol 39: 187-193, 1990.
25. Gali HU, Perchellet EM, Gao XM, Laks PE and Perchellet JP: Inhibitory effects of semisynthetic flavonoid derivatives on the biochemical markers of tumor promotion in mouse epidermis in vivo. Cancer Lett 72: 149-156, 1993.
26. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
27. Ferry DR, Smith A, Malkhandi J, Pyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ: Phase I clinical trial of the flavonoid Quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.
28. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC and Paull KD: Flavone acetic acid: novel agent with preclinical anti-tumour activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631-635, 1986.
29. Corbett TH, Bissery MC, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J and Valeriote F: Activity of flavone acetic acid (NSC-347512) against solid tumours in mice. Invest New Drugs 4: 207-220, 1986.
30. Finlay GJ, Smith GP, Fray LM and Baguley BC: Effect of flavone acetic acid in Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Int 80: 241-245, 1988.
31. Bibby MC, Double JA, Philips RM and Loadman PM: Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 55: 159-163, 1987.
32. Schroyens WA, Dodion PP, Sanders C, Loos M, Dethier NE, Delforge AR, Stryckmans PA and Kenis Y: In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSK 293015). Eur J Clin Cancer Oncol 23: 1135-1139, 1987.
33. Capolongo LS, Balconi G, Ubezio P, Giavazzi R, Taraboletti G, Regonesi A, Yoder OC and D'Incalci M: Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975) a new anticancer agent. Eur J Cancer Clin Oncol 23: 1529-1535, 1987.
34. Smith GP, Calverley SB, Smith MJ and Baguley BC: Flavone acetic acid (NSC 347512) induces hemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209-1211, 1987.
35. Bibby MC, Double JA, Philips RM, Loadman PM and Gummer JA: Experimental anti-tumour effects of flavone acetic acid (LM975). Progr Clin Biol Res 280: 243-246, 1988.
36. Duke CV, Double JA and Bibby MC: Flavone acetic acid (FAA (LM975), NSC 347512) induces a rapid massive necrosis in a murine transplantable adenocarcinoma (MAC26) Br J Cancer 58: 532, 1988.
37. Evelhoch JL, Bissery MC, Chabot GG, Simpson NE, McCoy CL, Heilbrun LK and Corbett TH: Flavone acetic acid (NSC347512) induced modulation of tumour physiology monitored by in vivo nuclear magnetic resonance spectroscopy Cancer Res 48: 4749-4755, 1988.
38. Hill S, Williams KB and Denekamp J: Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumor action. Eur J Cancer Clin Oncol 25: 1419-1424, 1989.
39. Zwi LJ, Baguley BC, Gavin JB and Wilson WR: The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br J Cancer 62: 231-237, 1990.
40. Peters CE, Trotter MJ and Chaplin DJ: Early spatial and temporal changes in tumour perfusion after administration of flavone acetic acid. Int J Radiat Biol 60: 341-348, 1991.
41. Murray JC, Smith KA and Thurston G: Flavone acetic acid induces a coagulopathy in mice. Br J Cancer 60: 729-733, 1989.
42. Murray CJ, Smith KA and Stern DM: Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumor necrosis factor. Eur J Cancer 27: 765-770, 1991.
43. Thomsen LL, Ching LM, Zhuang L, Gavin JB and Baguley BC: Tumour-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81, 1991.
44. Ching LM and Baguley BC: Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 23: 1047-1050, 1987.
45. Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA and Hornung RL: Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol 140: 3261-3265, 1988.
46. Mace KF, Hornung RL, Wiltrout RH and Young HA: Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 50: 1742-3 747, 1990.
47. Bibby MC and Double JA: Immunocompetence: a necessary component for the anti-tumour activity of flavone acetic acid (FAA). Br J Cancer 62: 516, 1990.
48. Bibby MC, Phillips RM, Double JA and Pratesi G: Antitumour activity of flavone acetic acid (NSC 347512) in mice - influence of immune status. Br J Cancer 63: 57-62, 1991.
49. Pratesi G, Rodolfo M, Rovetta G and Parmiani G: Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079-1083, 1990.
50. Bibby MC and Double JA: Flavone acetic acid - from laboratory to clinic and back. Anti-Cancer Drugs 4: 3-17, 1993.
51. Harmon A, Weiss U and Silverton JV: Structure of Rohitukine, the main alkaloid of amoora-rohituka (Syn. Aphanamixispolystachya) (meliaceae). Tetrahedron Lett 721-724, 1979.
52. Houghton PJ and Hairon Y: Further chromone alkaloids from Schumanniophyton-magnificum. Planta Med 53: 262-264, 1987.
53. Sedlacek HH, Hoffmann D, Schulz G, Czech J, Greifenberg B, Dickneite G and Kraemer HP: The chemotherapy of malignant diseases: research perspectives. Contributions to Oncology 34: Karger Verlag, München, 1989.
54. Czech J and Sedlacek HH: bFGF-stimulation of human tumor cell proliferation in vitro. Cancer Chemother Pharmacol 24: 72, 1989.
55. Centrella M and Canalis E: Transforming and nontransforming growth factors are present in medium conditioned by fetal rat calvariae. Proc Natl Acad Sci USA 88: 7335-7339, 1985.
56. Coffey RJ Jr, Leof EB, Shipley GD and Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 1232: 143-148, 1987.
57. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.
58. Austin CA, Patel S, Ono K, Nakane H and Fischer LM: Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 282: 883-889, 1992.
59. Traganos F, Ardelt B, Halko N, Bruno S and Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200-6208, 1992.
60. Yamashita Y, Kawada S and Nakano H: Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39: 737-744, 1990.
61. Kanter PM and Schwartz HS: A fluorescence enhancement assay for cellular DNA damage. Mol Pharmacol 22: 145-151, 1982.
62. Blake A and Peacock AR: The interaction of amino-acridines with nucleic acids. Biopolymers 6: 1225-1228, 1968.
63. Mossman T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation an cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
64. Pedrali-Noy G, Spadari S, Miller-Faures A, Miller AO, Kruppa J and Koch G: Synchronization of HeLa cell cultures by inhibition of DNA polymerase-α with aphidicolin. Nucleic Acids Res 8: 377-387, 1980.
65. Zieve GW, Turnbull D, Mullins JM and McIntosh JR: Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126: 397-405, 1980.
66. Suolinna EM, Buchsbaum RN and Racker E: The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res 35: 1865-1872, 1975.
67. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H and Aoike A: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260: 10-13, 1990.
68. Hosokawa N, Hosokawa Y, Sakai T, Yoshida M, Marui N, Nishino H, Kawai K and Aoike A: Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells. Int J Cancer 45: 1119-1124, 1990.
69. Morgan DO: Principles of cdk regulation. Nature 374: 131-134, 1995.
70. Rickert P, Seghezzi W, Shanahan F, Cho H and Lees E: Cyclin C/cdk8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 12: 2631-2640, 1996.
71. Müller R, Mumberg D and Lucibello FC: Signals and genes in the control of cell-cycle progression. Biochim Biophys Acta 1155: 151-179, 1993.
72. Bürger C, Wick M and Müller R: Lineage-specific regulation of cell cycle gene expression in differentiating myeloid cells. J Cell Sci 107: 2047-2054, 1994.
73. MacLachlan TK, Sang N and Giordano A: Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukar Gene Expr 5: 127-156, 1995.
74. La Thangue NB: DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr Opinion Cell Biol 6: 443-450, 1994.
75. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
76. Murray A: Cell cycle checkpoints. Curr Opinion Cell Biol 6: 872-876, 1994.
77. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and cdk inhibitors come of age. Cell 79: 573-582, 1994.
78. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO and Kim SH: Crystal structure of cyclin-dependent kinase 2. Nature 363: 595-602, 1993.
79. Ducommun B, Brambilla P and Draetta G: Mutations at sites involved in Suc1 binding inactivate cdc2. Mol Cell Biol 11: 6177-6184, 1991.
80. Gould KL, Moreno S, Owen DJ, Sazer S and Nurse P: Phosphorylation at Thr167 is required for Schizosaccharomyces pombe p34cdc2 function. EMBO J 10: 3297-3309, 1991.
81. Kobayashi H, Stewart E, Poon R, Adamczewski JP, Gannon J and Hunt T: Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. Mol Biol Cell 3: 1279-1294, 1992.
82. Lees EM and Harlow E: Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 13: 1194-1201, 1993.
83. Endicott JA, Nurse P and Johnson LN: Mutational analysis supports a sructural model for the cell cycle protein kinase p34. Protein Engineering 7: 243-253, 1994.
84. Zhang J, Sanchez RJ, Wang S, Guarnaccia C, Tossi A, Zahariev S and Pongor S: Substrate specificity of cdc2 kinase from human HeLa cells as determined with synthetic peptides and molecular modeling. Arch Biochem Biophys 315: 415-424, 1994.
85. Solomon MJ: The function(s) of CAK, the p34cdc2-activating kinase. Trends Biochem Sci 19: 496-500, 1994.
86. Ducommun B, Brambilla P, Felix MA, Franza BRJ, Karsenti E and Draetta G: cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 10: 3311-3319, 1991.
87. Desai D, Wessling HC, Fisher RP and Morgan DO: Effects of phosphorylation by CAK on cyclin binding by cdc2 and cdk2. Mol Cell Biol 15: 345-350, 1995.
88. Azzi L, Meijer L, Reed SI, Pidikiti R and Tung HYL: Interaction between the cell-cycle-control proteins p34cdc2 and p3CKShs2. Evidence for two cooperative binding domains in p3CKShs2. Eur J Biochem 203: 353-360, 1992.
89. Parge HE, Arvai AS, Murtadi DJ, Reed SI and Tainer JA: Human CksHs2 atomic structure: a role for its hexameric assembly in cell cycle control. Science 262: 387-395, 1993.
90. Azzi L, Meijer L, Ostvold AC, Lew J and Wang JH: Purification of a 15-kDa cdk4- and cdk5-binding protein. J Biol Chem 269: 13279-13288, 1994.
91. Galaktionov K and Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclin: evidence for multiple roles of mitotic cyclins. Cell 67: 1181-1194, 1991.
92. Zheng XF and Ruderman JV: Functional analysis of the P box, a domain in cyclin B required for the acitvatio of cdc25. Cell 75: 155-164, 1993.
93. Peter M and Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181-184, 1994.
94. Hannon GJ and Beach D: p15INK4B is a potential effector of TGFfl-induced cell cycle arrest. Nature 371: 257-261, 1994.
95. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG and Xiong Y: Growth suppression by p18, a P16INK4/MTS1- and p14INK4B/MTS2-related cdk6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952, 1994.
96. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-98, 1994.
97. King RW, Jackson PK and Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
98. Hershko A, Ganoth D, Sudakin V, Dahan A, Cohen LH, Luca FC, Ruderman JV and Eytan E: Components of a system that ligated cyclin to Ubiquitin and their regulation by the protein kinase cdc2. J Biol Chem 269: 4940-4946, 1994.
99. Lorca T, Devault A, Colas P, van Loon A, Fesquet D, Lazaro JB and Dorée M: Cyclin A-Cys41 does not undergo cell cycle-dependent degradation in Xenopus extracts. FEBS Lett 306: 90-93, 1992.
100. Holloway SL, Glotzer M, King RW and Murray AW: Anaphase is initiated by proteolysis rather than by the inactivatio of maturation-promoting factor. Cell 73: 1393-1402, 1993.
101. Ookata K, Hisanaga SI, Okano T, Tachibana K and Kishimoto T: Relocation and distinct subcellular localization of p34cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J 11: 1763-1772, 1992.
102. Pines J and Hunter T: The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. EMBO J 13: 3772-3781, 1994.
103. Bai C, Richman R and Elledge SJ: Human cyclin F. EMBO J 13: 6087-6098, 1994.
104. Dixon M and Webb EC: Enzymes, 3rd Ed. Academic Press, New York, NY, 1979.
105. O'Conner PM, Ferris DK, White GA, Pines J, Hunter T, Longo DL and Kohn KW: Relationship between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 3: 43-52, 1992.
106. cdc2/cyclin B. Cancer Res 52: 1823-1829, 1992.
107. 2 arrest in Chinese hamster ovary cells. Cancer Res 50: 3761-3766, 1990.
108. Lock RB and Ross WE: Possible role for p34cdc2 kinase in Etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res 50: 3767-2771, 1990.
109. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 52: 1817-1822, 1992.
110. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E and Tsai LH: A family of human cdc2-related protein kinases. EMBO J 11: 2909-2917, 1992.
111. Mcikrantz W, Gisselbrecht S, Tam SW and Schlegel R: Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758, 1994.
112. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW and Greenberg AH: Premature p34cdc2 activation required for apoptosis. Science 263: 1143-1145, 1994.
113. Fotedar R, Flatt J, Gupta S, Margolis RL, Fittzgerald P, Messier H and Fotedar A: Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol Cell Biol 15: 932-952, 1995.
114. Oberhammer FA, Hochegger K, Fröschl G, Tiefenbacher R and Pavelka MJ: Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activatio of cdc2 kinase. Cell Biol 126: 827-837, 1994.
115. Kharbanda S, Saleem A, Datta R, Yuan ZM, Weichselbaum R and Kufe D: Ionizing radiation induces rapid tyrosine phosporylation of p34cdc2. Cancer Res 54: 1412-1414, 1994.
116. Demarcq C, Bunch RT, Creswell D and Easterman A: The role of cell cycle progression in cisplatin induced apoptosis in Chinese hamster ovary cells. Cell Growth Different 5: 983-993, 1994.
117. 2. Nature 254: 245-247, 1975.
118. Kimler BF, Schneiderman MH and Leeper DB: Induction of concentration-dependent blockade in the G2 phase of the cell cycle by cancer chemotherapeutic agents. Cancer Res 38: 809-814, 1978.
119. 2-M. Cancer Res 53: 1328-1331, 1993.
120. 2 and mitotic Chinese hamster ovary cell progression. Cancer Res 49: 4752-4747, 1989.
121. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
122. 1 phase of nontransformed mammalian cells are absent in transformed cells. Proc Natl Acad Sci USA 89: 8626-8630, 1992.
123. 2 block caused by Staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 192: 122-127, 1991.
124. 1 phase of the cell cycle Proc Natl Acad Sci USA 88: 7580-7584, 1991.
125. Bruno S, Ardelt B, Skierski JS, Traganos F and Darzynkiewicz Z: Different effects of Staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 52: 470-473, 1992.
126. Kitagawa M, Higashi H, Suzuki-Takahashi I, Okabe T, Ogino H, Taya Y, Nishimura S and Okuyama A: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9: 2549-2557, 1994.
127. Abraham RT, Acquarone M, Andersen A, Asensi A, Bellé R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, Glab N, Houghton PJ, Hendriks H, Kloareg B, Lippai M, Marie D, Maro B, Meijer L, Mester J, Mulner-Lorillon O, Poulet SA, Schierenberg E, Schutte B, Vaulot D and Verlhac MH: Cellular effects of Olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 83: 105-120, 1995.
128. Mahoney CW, Azzi A and Huang KP: Effects of Suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem 265: 5424-5428, 1990.
129. De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E and Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735-2740, 1996.
130. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massagué J and Pavletich NP: Mechanism of cdk activation revealed by the structure of a cyclin A-cdk2 comples. Nature 376: 313-320, 1995.
131. Wilson IA and Stanfield RL: Antibody-antigen interactions. Curr Opinion Struct Biol 3: 113-118, 1993.
132. Bibby MC, Philips RM and Double JA: Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512) Cancer Chemother Pharmacol 24: 87-94, 1989.
133. Collett MS and Erikson RL: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sci USA 75: 2021-2024, 1978.